<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375387</url>
  </required_header>
  <id_info>
    <org_study_id>SP1046</org_study_id>
    <secondary_id>2010-023164-40</secondary_id>
    <nct_id>NCT01375387</nct_id>
  </id_info>
  <brief_title>Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males</brief_title>
  <official_title>A Phase I, Randomized Double-blind, Placebo-controlled, Single-center, Single-dose, Three-way Cross-over Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Lacosamide Tablets in Healthy Male Chinese and Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      lacosamide following single oral administration of lacosamide 100 mg, 200 mg and 400 mg in
      healthy male Chinese and Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) of lacosamide in plasma.</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from 0 to the time of the last quantifiable concentration (AUC(0-t)) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from 0 to infinity (AUC) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/F) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean resident time (MRT) of lacosamide in plasma.</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First order terminal elimination rate constant (λZ ) of lacosamide in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration (Cmax) of SPM12809 in plasma.</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to the time of the last quantifiable concentration (AUC(0-t)) of SPM12809 in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to infinity (AUC) of SPM12809 in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax) of SPM12809 in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½) of SPM12809 in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First order terminal elimination rate constant (λZ ) of SPM12809 in plasma</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of drug excreted in urine (Ae) of lacosamide and SPM12809</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of dose excreted in urine (fe) of lacosamide and SPM12809</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) of lacosamide and SPM12809</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent formation clearance of metabolites (CLfm/F)</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Ratio</measure>
    <time_frame>Multiple sampling from 0 to 72 hours following single dose in each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Lacosamide 100 mg, Japanese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Lacosamide 100 mg tablet plus 3 placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 100 mg, Chinese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Lacosamide 100 mg tablet plus 3 placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 200 mg, Japanese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Lacosamide 100 mg tablets plus 2 placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 200 mg, Chinese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Lacosamide 100 mg tablets plus 2 placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 400 mg, Japanese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Lacosamide 100 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 400 mg, Chinese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Lacosamide 100 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator, Japanese</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator, Chinese</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>100 mg oral tablet, single dose</description>
    <arm_group_label>Lacosamide 100 mg, Japanese</arm_group_label>
    <arm_group_label>Lacosamide 100 mg, Chinese</arm_group_label>
    <other_name>Vimpat®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Lacosamide 2 X 100 mg tablet</description>
    <arm_group_label>Lacosamide 200 mg, Japanese</arm_group_label>
    <arm_group_label>Lacosamide 200 mg, Chinese</arm_group_label>
    <other_name>Vimpat®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Lacosamide 4 X 100mg tablet</description>
    <arm_group_label>Lacosamide 400 mg, Japanese</arm_group_label>
    <arm_group_label>Lacosamide 400 mg, Chinese</arm_group_label>
    <other_name>Vimpat®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo 3</intervention_name>
    <description>Placebo - 3 tablets</description>
    <arm_group_label>Lacosamide 100 mg, Japanese</arm_group_label>
    <arm_group_label>Lacosamide 100 mg, Chinese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo 4</intervention_name>
    <description>Placebo - 4 tablets</description>
    <arm_group_label>Placebo Comparator, Japanese</arm_group_label>
    <arm_group_label>Placebo Comparator, Chinese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>Placebo - 2 tablets</description>
    <arm_group_label>Lacosamide 200 mg, Japanese</arm_group_label>
    <arm_group_label>Lacosamide 200 mg, Chinese</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Chinese or Japanese volunteers

        Exclusion Criteria:

          -  Subject has participated or is participating in any other clinical studies of
             Lacosamide within the last 3 months

          -  Subject is not healthy (eg, taking any drug treatments, excessive amount of alcohol,
             cigarettes or caffeine, having any psychological or emotional problems, a drug/alcohol
             abuse, abnormal diet, having abnormal safety parameters)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vimpat</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Japanese male</keyword>
  <keyword>Healthy Chinese male</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

